



REPORTED SALES vs. PRIOR PERIOD (\$MM)

| | FIRST QUARTER | | | | |
|---|-----------------|--------------|-----------------|-----------------------------------|-----------------|
| | <u>2022</u> | <u>2021</u> | % Change | | |
| | | | <u>Reported</u> | <u>Operational</u> ⁽¹⁾ | <u>Currency</u> |
| CONSUMER HEALTH SEGMENT ^(2,3) | | | | | |
| <u>OTC</u> ⁽⁵⁾ | | | | | |
| US | \$ 670 | 599 | 11.8% | 11.8% | - |
| Intl | 791 | 673 | 17.5% | 21.7% | -4.2% |
| WW | <u>1,461</u> | <u>1,273</u> | 14.8% | 17.1% | -2.3% |
| <u>SKIN HEALTH / BEAUTY</u> | | | | | |
| US | 544 | 634 | -14.2% | -14.2% | - |
| Intl | 468 | 529 | -11.6% | -7.1% | -4.5% |
| WW | <u>1,012</u> | <u>1,163</u> | -13.0% | -11.0% | -2.0% |
| <u>ORAL CARE</u> | | | | | |
| US | 143 | 163 | -12.6% | -12.6% | - |
| Intl | 223 | 254 | -12.0% | -8.6% | -3.4% |
| WW | <u>366</u> | <u>417</u> | -12.2% | -10.2% | -2.0% |
| <u>BABY CARE</u> | | | | | |
| US | 85 | 96 | -11.5% | -11.5% | - |
| Intl | 270 | 293 | -7.7% | -4.8% | -2.9% |
| WW | <u>355</u> | <u>389</u> | -8.6% | -6.4% | -2.2% |
| <u>WOMEN'S HEALTH</u> | | | | | |
| US | 3 | 3 | 7.2% | 7.2% | - |
| Intl | 224 | 219 | 2.5% | 8.3% | -5.8% |
| WW | <u>228</u> | <u>222</u> | 2.6% | 8.3% | -5.7% |
| <u>WOUND CARE / OTHER</u> | | | | | |
| US | 112 | 115 | -3.3% | -3.3% | - |
| Intl | 52 | 61 | -15.3% | -14.5% | -0.8% |
| WW | <u>164</u> | <u>177</u> | -7.4% | -7.2% | -0.2% |
| TOTAL CONSUMER HEALTH | | | | | |
| US | 1,557 | 1,611 | -3.4% | -3.4% | - |
| Intl | 2,029 | 2,030 | 0.0% | 4.1% | -4.1% |
| WW | <u>\$ 3,586</u> | <u>3,641</u> | -1.5% | 0.8% | -2.3% |

See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD (\$MM)

| | FIRST QUARTER | | | | |
|--|----------------------|--------------|-----------------|-----------------------------------|-----------------|
| | 2022 | 2021 | % Change | | |
| | | | Reported | Operational ⁽¹⁾ | Currency |
| PHARMACEUTICAL SEGMENT ^(2,3) | | | | | |
| IMMUNOLOGY | | | | | |
| US | \$ 2,501 | 2,413 | 3.7% | 3.7% | - |
| Intl | 1,617 | 1,501 | 7.7% | 13.7% | -6.0% |
| WW | <u>4,119</u> | <u>3,914</u> | 5.2% | 7.5% | -2.3% |
| REMICADE | | | | | |
| US | 358 | 489 | -26.8% | -26.8% | - |
| US Exports ⁽⁴⁾ | 80 | 57 | 40.5% | 40.5% | - |
| Intl | 225 | 232 | -2.6% | -1.0% | -1.6% |
| WW | <u>663</u> | <u>777</u> | -14.7% | -14.2% | -0.5% |
| SIMPONI / SIMPONI ARIA | | | | | |
| US | 287 | 255 | 12.5% | 12.5% | - |
| Intl | 283 | 307 | -7.6% | -1.9% | -5.7% |
| WW | <u>571</u> | <u>562</u> | 1.5% | 4.7% | -3.2% |
| STELARA | | | | | |
| US | 1,379 | 1,331 | 3.6% | 3.6% | - |
| Intl | 909 | 817 | 11.2% | 17.8% | -6.6% |
| WW | <u>2,288</u> | <u>2,148</u> | 6.5% | 9.0% | -2.5% |
| TREMFYA | | | | | |
| US | 391 | 274 | 42.7% | 42.7% | - |
| Intl | 199 | 143 | 38.8% | 47.9% | -9.1% |
| WW | <u>590</u> | <u>418</u> | 41.3% | 44.5% | -3.2% |
| OTHER IMMUNOLOGY | | | | | |
| US | 6 | 7 | -3.2% | -3.2% | - |
| Intl | 0 | 2 | * | * | * |
| WW | <u>6</u> | <u>8</u> | -22.0% | -22.0% | - |
| INFECTIOUS DISEASES ⁽⁵⁾ | | | | | |
| US | 461 | 512 | -10.0% | -10.0% | - |
| Intl | 836 | 485 | 72.3% | 78.6% | -6.3% |
| WW | <u>1,297</u> | <u>998</u> | 30.0% | 33.1% | -3.1% |
| COVID-19 VACCINE | | | | | |
| US | 75 | 100 | -24.9% | -24.9% | - |
| Intl | 382 | 0 | * | * | * |
| WW | <u>457</u> | <u>100</u> | * | * | * |
| EDURANT / rilpivirine | | | | | |
| US | 9 | 10 | -12.6% | -12.6% | - |
| Intl | 239 | 233 | 2.5% | 10.5% | -8.0% |
| WW | <u>248</u> | <u>243</u> | 1.8% | 9.6% | -7.8% |
| PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA | | | | | |
| US | 369 | 380 | -3.1% | -3.1% | - |
| Intl | 132 | 166 | -20.3% | -15.9% | -4.4% |
| WW | <u>501</u> | <u>546</u> | -8.3% | -6.9% | -1.4% |
| OTHER INFECTIOUS DISEASES | | | | | |
| US | 8 | 21 | -62.5% | -62.5% | - |
| Intl | 83 | 87 | -3.8% | 1.6% | -5.4% |
| WW | <u>91</u> | <u>108</u> | -15.3% | -11.0% | -4.3% |

REPORTED SALES vs. PRIOR PERIOD (\$MM)

| | FIRST QUARTER | | | | |
|---|----------------------|--------------|-----------------|-----------------------------------|-----------------|
| | <u>2022</u> | <u>2021</u> | <u>% Change</u> | | |
| | | | <u>Reported</u> | <u>Operational</u> ⁽¹⁾ | <u>Currency</u> |
| <u>NEUROSCIENCE</u> ⁽⁵⁾ | | | | | |
| US | 843 | 771 | 9.3% | 9.3% | - |
| Intl | 898 | 943 | -4.8% | 1.5% | -6.3% |
| WW | <u>1,741</u> | <u>1,715</u> | 1.5% | 5.0% | -3.5% |
| <u>CONCERTA / Methylphenidate</u> | | | | | |
| US | 35 | 47 | -26.5% | -26.5% | - |
| Intl | 122 | 123 | -1.3% | 3.5% | -4.8% |
| WW | <u>157</u> | <u>171</u> | -8.3% | -4.8% | -3.5% |
| <u>INVEGA TRINZA / TREVICTA</u> | | | | | |
| US | 661 | 589 | 12.2% | 12.2% | - |
| Intl | 387 | 376 | 3.0% | 9.9% | -6.9% |
| WW | <u>1,048</u> | <u>965</u> | 8.6% | 11.3% | -2.7% |
| <u>RISPERDAL CONSTA</u> | | | | | |
| US | 63 | 67 | -6.4% | -6.4% | - |
| Intl | 66 | 89 | -26.1% | -19.6% | -6.5% |
| WW | <u>129</u> | <u>157</u> | -17.6% | -13.9% | -3.7% |
| <u>OTHER NEUROSCIENCE</u> | | | | | |
| US | 84 | 67 | 25.5% | 25.5% | - |
| Intl | 323 | 355 | -8.9% | -2.8% | -6.1% |
| WW | <u>408</u> | <u>422</u> | -3.5% | 1.7% | -5.2% |
| <u>ONCOLOGY</u> | | | | | |
| US | 1,582 | 1,377 | 14.9% | 14.9% | - |
| Intl | 2,369 | 2,193 | 8.0% | 15.0% | -7.0% |
| WW | <u>3,950</u> | <u>3,570</u> | 10.6% | 14.9% | -4.3% |
| <u>DARZALEX</u> | | | | | |
| US | 953 | 691 | 37.9% | 37.9% | - |
| Intl | 903 | 674 | 34.0% | 42.7% | -8.7% |
| WW | <u>1,856</u> | <u>1,365</u> | 36.0% | 40.3% | -4.3% |
| <u>ERLEADA</u> | | | | | |
| US | 206 | 171 | 20.3% | 20.3% | - |
| Intl | 194 | 90 | * | * | * |
| WW | <u>400</u> | <u>261</u> | 53.0% | 57.5% | -4.5% |
| <u>IMBRUVICA</u> | | | | | |
| US | 370 | 444 | -16.7% | -16.7% | - |
| Intl | 668 | 680 | -1.8% | 4.5% | -6.3% |
| WW | <u>1,038</u> | <u>1,125</u> | -7.7% | -3.9% | -3.8% |
| <u>ZYTIGA / abiraterone acetate</u> | | | | | |
| US | 19 | 50 | -62.1% | -62.1% | - |
| Intl | 520 | 588 | -11.6% | -5.7% | -5.9% |
| WW | <u>539</u> | <u>638</u> | -15.6% | -10.1% | -5.5% |
| <u>OTHER ONCOLOGY</u> | | | | | |
| US | 34 | 21 | 63.1% | 63.1% | - |
| Intl | 84 | 161 | -47.7% | -44.6% | -3.1% |
| WW | <u>118</u> | <u>182</u> | -35.1% | -32.3% | -2.8% |

REPORTED SALES vs. PRIOR PERIOD (\$MM)

| | FIRST QUARTER | | | | |
|--|----------------------|---------------|-----------------|-----------------------------------|-----------------|
| | <u>2022</u> | <u>2021</u> | <u>% Change</u> | | |
| | | | <u>Reported</u> | <u>Operational</u> ⁽¹⁾ | <u>Currency</u> |
| <u>PULMONARY HYPERTENSION</u> | | | | | |
| US | 572 | 573 | -0.2% | -0.2% | - |
| Intl | 279 | 288 | -2.9% | 4.0% | -6.9% |
| WW | <u>852</u> | <u>861</u> | -1.1% | 1.2% | -2.3% |
| <u>OPSUMIT</u> | | | | | |
| US | 273 | 272 | 0.5% | 0.5% | - |
| Intl | 170 | 179 | -4.8% | 2.0% | -6.8% |
| WW | <u>443</u> | <u>450</u> | -1.6% | 1.1% | -2.7% |
| <u>UPTRAVI</u> | | | | | |
| US | 269 | 259 | 3.9% | 3.9% | - |
| Intl | 56 | 46 | 20.9% | 28.8% | -7.9% |
| WW | <u>325</u> | <u>305</u> | 6.5% | 7.7% | -1.2% |
| <u>OTHER PULMONARY HYPERTENSION</u> | | | | | |
| US | 30 | 42 | -29.0% | -29.0% | - |
| Intl | 53 | 63 | -15.2% | -8.4% | -6.8% |
| WW | <u>83</u> | <u>105</u> | -20.8% | -16.8% | -4.0% |
| <u>CARDIOVASCULAR / METABOLISM / OTHER</u> ⁽⁵⁾ | | | | | |
| US | 672 | 799 | -15.8% | -15.8% | - |
| Intl | 238 | 245 | -3.0% | 0.9% | -3.9% |
| WW | <u>910</u> | <u>1,044</u> | -12.8% | -11.9% | -0.9% |
| <u>XARELTO</u> | | | | | |
| US | 508 | 589 | -13.8% | -13.8% | - |
| Intl | - | - | - | - | - |
| WW | <u>508</u> | <u>589</u> | -13.8% | -13.8% | - |
| <u>INVOKANA / INVOKAMET</u> | | | | | |
| US | 60 | 87 | -30.7% | -30.7% | - |
| Intl | 68 | 63 | 7.5% | 11.1% | -3.6% |
| WW | <u>128</u> | <u>150</u> | -14.6% | -13.1% | -1.5% |
| <u>OTHER</u> | | | | | |
| US | 104 | 122 | -14.9% | -14.9% | - |
| Intl | 170 | 182 | -6.6% | -2.6% | -4.0% |
| WW | <u>274</u> | <u>305</u> | -10.0% | -7.5% | -2.5% |
| <u>TOTAL PHARMACEUTICAL</u> | | | | | |
| US | 6,632 | 6,446 | 2.9% | 2.9% | - |
| Intl | 6,237 | 5,655 | 10.3% | 16.7% | -6.4% |
| WW | <u>\$ 12,869</u> | <u>12,101</u> | 6.3% | 9.3% | -3.0% |

See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD (\$MM)

| | FIRST QUARTER | | | | |
|--|----------------------|--------------|-----------------|-----------------------------------|-----------------|
| | <u>2022</u> | <u>2021</u> | <u>% Change</u> | | |
| | | | <u>Reported</u> | <u>Operational</u> ⁽¹⁾ | <u>Currency</u> |
| <u>MEDTECH SEGMENT</u> ^(2,3,6) | | | | | |
| <u>INTERVENTIONAL SOLUTIONS</u> | | | | | |
| US | \$ 494 | 434 | 13.8% | 13.8% | - |
| Intl | 597 | 514 | 16.2% | 20.4% | -4.2% |
| WW | <u>1,092</u> | <u>949</u> | 15.1% | 17.4% | -2.3% |
| <u>ORTHOPAEDICS</u> | | | | | |
| US | 1,289 | 1,249 | 3.2% | 3.2% | - |
| Intl | 899 | 864 | 4.1% | 9.1% | -5.0% |
| WW | <u>2,188</u> | <u>2,113</u> | 3.5% | 5.6% | -2.1% |
| <u>HIPS</u> | | | | | |
| US | 225 | 209 | 7.3% | 7.3% | - |
| Intl | 164 | 146 | 12.2% | 17.0% | -4.8% |
| WW | <u>389</u> | <u>356</u> | 9.3% | 11.3% | -2.0% |
| <u>KNEES</u> | | | | | |
| US | 201 | 185 | 8.6% | 8.6% | - |
| Intl | 138 | 132 | 4.1% | 9.1% | -5.0% |
| WW | <u>339</u> | <u>317</u> | 6.7% | 8.8% | -2.1% |
| <u>TRAUMA</u> | | | | | |
| US | 475 | 450 | 5.5% | 5.5% | - |
| Intl | 273 | 282 | -3.3% | 2.2% | -5.5% |
| WW | <u>748</u> | <u>733</u> | 2.1% | 4.2% | -2.1% |
| <u>SPINE, SPORTS & OTHER</u> | | | | | |
| US | 387 | 404 | -4.1% | -4.1% | - |
| Intl | 324 | 303 | 7.0% | 11.7% | -4.7% |
| WW | <u>712</u> | <u>707</u> | 0.6% | 2.7% | -2.1% |

REPORTED SALES vs. PRIOR PERIOD (\$MM)

| | FIRST QUARTER | | | | |
|--------------------------------------|----------------------|--------------|-----------------|--|-----------------|
| | <u>2022</u> | <u>2021</u> | <u>Reported</u> | <u>% Change Operational ⁽¹⁾</u> | <u>Currency</u> |
| <u>SURGERY</u> | | | | | |
| US | 921 | 898 | 2.5% | 2.5% | - |
| Intl | 1,513 | 1,474 | 2.7% | 6.6% | -3.9% |
| WW | <u>2,434</u> | <u>2,372</u> | 2.6% | 5.0% | -2.4% |
| <u>ADVANCED</u> | | | | | |
| US | 417 | 405 | 3.0% | 3.0% | - |
| Intl | 729 | 713 | 2.2% | 5.4% | -3.2% |
| WW | <u>1,146</u> | <u>1,118</u> | 2.5% | 4.5% | -2.0% |
| <u>GENERAL</u> | | | | | |
| US | 504 | 493 | 2.1% | 2.1% | - |
| Intl | 784 | 761 | 3.1% | 7.7% | -4.6% |
| WW | <u>1,288</u> | <u>1,254</u> | 2.7% | 5.5% | -2.8% |
| <u>VISION</u> | | | | | |
| US | 521 | 472 | 10.4% | 10.4% | - |
| Intl | 736 | 673 | 9.4% | 16.4% | -7.0% |
| WW | <u>1,257</u> | <u>1,145</u> | 9.8% | 13.9% | -4.1% |
| <u>CONTACT LENSES / OTHER</u> | | | | | |
| US | 400 | 371 | 7.7% | 7.7% | - |
| Intl | 511 | 486 | 5.1% | 12.9% | -7.8% |
| WW | <u>910</u> | <u>857</u> | 6.2% | 10.6% | -4.4% |
| <u>SURGICAL</u> | | | | | |
| US | 121 | 101 | 20.2% | 20.2% | - |
| Intl | 226 | 187 | 20.5% | 25.7% | -5.2% |
| WW | <u>347</u> | <u>288</u> | 20.4% | 23.8% | -3.4% |
| <u>TOTAL MEDTECH</u> | | | | | |
| US | 3,225 | 3,054 | 5.6% | 5.6% | - |
| Intl | 3,746 | 3,525 | 6.3% | 11.1% | -4.8% |
| WW | <u>\$ 6,971</u> | <u>6,579</u> | 5.9% | 8.5% | -2.6% |

Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

* Percentage greater than 100% or not meaningful

(1) Operational growth excludes the effect of translational currency

(2) Unaudited

(3) Certain prior year amounts have been reclassified to conform to current year product disclosures

(4) Reported as U.S. sales

(5) Refer to supplemental sales information schedule

(6) Previously referred to as Medical Devices

Supplemental Sales Information

(Dollars in Millions)

Certain prior year amounts have been reclassified to conform to current year product disclosures

| | 2020 | 2021 | | | | 2021 |
|--|------------------|--------------|--------------|--------------|--------------|------------------|
| | <u>Full Year</u> | <u>Q1</u> | <u>Q2</u> | <u>Q3</u> | <u>Q4</u> | <u>Full Year</u> |
| CONSUMER HEALTH SEGMENT ⁽¹⁾ | | | | | | |
| <u>OTC ⁽²⁾</u> | | | | | | |
| US | 2,460 | 599 | 675 | 686 | 633 | 2,594 |
| Intl | 2,761 | 673 | 752 | 798 | 811 | 3,034 |
| WW | <u>5,221</u> | <u>1,273</u> | <u>1,426</u> | <u>1,484</u> | <u>1,444</u> | <u>5,627</u> |
| PHARMACEUTICAL SEGMENT ⁽¹⁾ | | | | | | |
| <u>INFECTIOUS DISEASES ⁽²⁾</u> | | | | | | |
| <u>OTHER INFECTIOUS DISEASES</u> | | | | | | |
| US | 104 | 21 | 16 | 18 | 11 | 66 |
| Intl | 292 | 87 | 71 | 82 | 57 | 297 |
| WW | <u>396</u> | <u>108</u> | <u>88</u> | <u>99</u> | <u>68</u> | <u>363</u> |
| <u>NEUROSCIENCE ⁽²⁾</u> | | | | | | |
| <u>OTHER NEUROSCIENCE</u> | | | | | | |
| US | 298 | 67 | 91 | 81 | 99 | 338 |
| Intl | 1,312 | 355 | 373 | 298 | 342 | 1,368 |
| WW | <u>1,610</u> | <u>422</u> | <u>464</u> | <u>379</u> | <u>441</u> | <u>1,706</u> |
| <u>CARDIOVASCULAR / METABOLISM / OTHER ^(2,3)</u> | | | | | | |
| <u>OTHER</u> | | | | | | |
| US | 600 | 122 | 116 | 98 | 110 | 446 |
| Intl | 794 | 182 | 178 | 173 | 140 | 673 |
| WW | <u>1,394</u> | <u>305</u> | <u>293</u> | <u>271</u> | <u>250</u> | <u>1,119</u> |

Note: Columns and rows within tables may not add due to rounding

(1) Unaudited

(2) Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes in their respective regions

(3) Other is inclusive of PROCIT / EPREX, which was previously disclosed separately